Company
Teleflex
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
61
510(k), De Novo and PMA
Device trials
7
As lead sponsor, any status
Adverse event reports
4,814
Received Nov 1, 2025 to Nov 19, 2026
Recall records
1,198
One per recalled product
Teleflex is on our public-company list (ticker TFX). Names searched as well: Arrow International. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.
Listed
TFX
NYSE · TELEFLEX INC
Public float
$2.30B
Value of shares held by non-insiders on Jun 29, 2025
Revenue
$1.99B
Fiscal year ending Dec 31, 2025
Net income
-$906M
Fiscal year ending Dec 31, 2025
R&D spending
$145M
Fiscal year ending Dec 31, 2025
Cash
$430M
As of Sep 30, 2026
Long-term debt
$1.62B
As of Sep 30, 2026
Shares outstanding
39.7M
As of Nov 3, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | $1.14B | – |
| 2024 | – | – | $130M | – |
| 2023 | – | – | $646M | – |
| 2022 | – | – | $744M | – |
| 2021 | – | – | $400M | – |
Private placements (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
Company details
From the company's latest Form D.
- Legal name
- Arrow Allergy, Inc.; Sigma Pharmaceuticals Ltd
- Headquarters
- Erie, Colorado
- Incorporated
- Delaware in 2021
- Entity type
- Corporation
- Revenue range
- No Revenues
- Industry filed under
- Other Health Care
- SEC filer
- CIK 1858360 ↗, CIK 1472870 ↗
Executives, directors and promoters
As listed on the latest Form D.
1 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
The 8 newest of 61 since 2015.
K262531 · Decided Oct 27, 2026 · 97 days after receipt
Device type: Instrument, Biopsy (KNW) · GI, Urology & Nephrology
K261418 · Decided Sep 23, 2026 · 146 days after receipt
Device type: Catheter, Straight (EZD) · GI, Urology & Nephrology
K262056 · Decided Aug 5, 2026 · 48 days after receipt
Device type: Catheter, Retention Type, Balloon (EZL) · GI, Urology & Nephrology
58 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery LesionsPivotal-lookingRecruiting
NCT07258290 · 1,859 participants (planned) · Start Jun 11, 2026 · Primary completion Jun 2029
Device: Freesolve RMS; Xience DES · For: Coronary Disease; Heart Diseases; Cardiovascular Diseases and 12 more
Sites: Washington D.C., District of Columbia; Dallas, Texas; Plano, Texas · 7 sites in all
NCT06779630 · 150 participants (planned) · Start Jul 18, 2025 · Primary completion Sep 2027
Device: Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System · For: Coronary Artery Disease
Sites: Concord, California; Wichita, Kansas; Boston, Massachusetts · 23 sites in all
- A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access DevicesRecruiting
NCT06604039 · 2,500 participants (planned) · Start Dec 8, 2024 · Primary completion Dec 7, 2034
Device: Central venous catheter · For: Vascular Access Device
Sites: Huntsville, Alabama; Loma Linda, California; Boston, Massachusetts
4 more trials with a free account
Reports received
4,814
Received Nov 1, 2025 to Nov 19, 2026. Includes 18 of another or unstated type.
Malfunction reports
4,532
94% of reports
Injury reports
254
5.3% of reports
Death reports
10
0.2% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 341 | 23 | 1 | 1 |
| Jan 24 | 456 | 27 | 3 | 0 |
| Feb 24 | 365 | 23 | 1 | 0 |
| Mar 24 | 402 | 31 | 1 | 0 |
| Apr 24 | 355 | 19 | 2 | 1 |
| May 24 | 567 | 36 | 1 | 1 |
| Jun 24 | 467 | 26 | 0 | 0 |
| Jul 24 | 515 | 20 | 0 | 0 |
| Aug 24 | 489 | 44 | 1 | 0 |
| Sep 24 | 423 | 21 | 1 | 0 |
| Oct 24 | 475 | 38 | 2 | 2 |
| Nov 24 | 435 | 50 | 0 | 0 |
| Dec 24 | 367 | 37 | 4 | 0 |
| Jan 25 | 451 | 26 | 1 | 0 |
| Feb 25 | 353 | 41 | 1 | 0 |
| Mar 25 | 419 | 14 | 0 | 0 |
| Apr 25 | 397 | 26 | 1 | 0 |
| May 25 | 384 | 24 | 0 | 0 |
| Jun 25 | 426 | 22 | 0 | 0 |
| Jul 25 | 433 | 20 | 1 | 0 |
| Aug 25 | 367 | 19 | 1 | 0 |
| Sep 25 | 377 | 18 | 1 | 0 |
| Oct 25 | 348 | 29 | 0 | 0 |
| Nov 25 | 372 | 34 | 0 | 0 |
| Dec 25 | 372 | 21 | 1 | 0 |
| Jan 26 | 365 | 15 | 2 | 0 |
| Feb 26 | 347 | 21 | 3 | 0 |
| Mar 26 | 383 | 25 | 0 | 1 |
| Apr 26 | 451 | 18 | 0 | 0 |
| May 26 | 357 | 14 | 1 | 0 |
| Jun 26 | 437 | 15 | 1 | 4 |
| Jul 26 | 431 | 21 | 0 | 3 |
| Aug 26 | 393 | 18 | 0 | 7 |
| Sep 26 | 309 | 21 | 0 | 2 |
| Oct 26 | 315 | 31 | 2 | 1 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2639-2026 · Started May 7, 2026 · Posted by FDA Jul 1, 2026
Reason given: Due to out-of-specification, or potential out-of-specification, levels of endotoxins
Cause as FDA categorized it: Device Design · Device type: Gauze/Sponge, Internal (EFQ)
- PARACENTESIS KIT, REF: AK-00376, ASK-00376-VCUOpen, Classified
Z-2363-2026 · Started Apr 21, 2026 · Posted by FDA Jun 13, 2026
Reason given: Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Paracentesis Tray (PYC)
Z-2364-2026 · Started Apr 21, 2026 · Posted by FDA Jun 13, 2026
Reason given: Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or...
Cause as FDA categorized it: Nonconforming Material/Component · Device type: Anesthesia Conduction Kit (CAZ)
1,195 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.